Close

Add to pipeline

Save Close
You are viewing a limited version of this profile. To access i3's full capabilities.
ZYMtronix
Save
Company logo (jpg or png)
Parent company
Edit alternate names

Short description

Manufacturer of methods and materials to immobilize enzymes for solutions in coatings, assay, batch, and continuous flow forms

Founded in 2013
Founded in

Company type Private Public ()
Company type

Industry Group materials & chemicals

Sector biotechnology

TRL Range 7-8
TRL 1 Basic research
TRL 2 Technology formulation
TRL 3 Applied research
TRL 4 Small scale prototype
TRL 5 Large scale prototype
TRL 6 Prototype system
TRL 7 Demonstration system
TRL 8 First of a kind commercial system
TRL 9 Full commercial application
TRL Range

Ticker

Headquarters Ithaca, NY Ithaca, United States
Address
City
State
Zip
Country

Parent Companies

Website

Updated by Juan Diego Alonso at Zymtronix on 04/02/2016

Edited by Cleantech Group on 04/30/2024

Traction
  • 0 M&A items
tags
Similar companies
Customers
Save
Add Customer
Date Company
02/19/2015

Codexis Codexis

R&D Collaboration

Confirmed by Codexis
Delete
Partnerships
Save
Add Partnership
Date Partner Type
02/16/2023
Ginkgo Bioworks Ginkgo Bioworks
Zymtronix and Gingko Bioworks partner to industrialize cell-free biomanufacturing.
View source    
Confirmed by Ginkgo Bioworks
Development Partner
Delete
Investment Rounds
Save

IPO INFORMATION

Date

IPO status

IPO Type

Amount

Initial shares

Ticker symbol

Exchange listed

Prospectus URL

Prospectus

Source URL

Source

Description

Cancel Save
Add Investment
Date Investors Type Amount
02/11/2020 Tate & Lyle Tate & Lyle (1)
Post-money valuation of
The partnership includes an investment by Tate & Lyle in Zymtronix's 'cutting edge' enzyme immobilization platform.
 Seed
Delete
Click to add IPO information
Products
Save
Add Product
Product image Name Product status Revenue model Cost metrics

ZYM-Optimizer

Produce immobilization-screening plates, provide data analysis guidance, and deliver mg to g quantities of target-immobilized enzymes at up to 40% enzyme loading, in under 2 weeks.

 Pilot/Early Revenue Service - Per Unit
$/kW (current)
$/kW (projected)
$/kWh (current)
$/kWh (projected)
Delete
You are viewing a limited version of this profile. To access i3's full capabilities.
Back to top

Preload svg text font